78988 20240104111811.0 doi 10.14336/AD.2018.0917 sideral 111569 ART-2019-111569 eng Calvo, Ana C. Universidad de Zaragoza (orcid)0000-0001-5193-7782 Collagen XIX Alpha 1 improves prognosis in amyotrophic lateral sclerosis 2019 Access copy available to the general public Unrestricted The identification of more reliable diagnostic or prognostic biomarkers in age-related neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), is urgently needed. The objective in this study was to identify more reliable prognostic biomarkers of ALS mirroring neurodegeneration that could be of help in clinical trials. A total of 268 participants from three cohorts were included in this study. The muscle and blood cohorts were analyzed in two cross-sectional studies, while the serial blood cohort was analyzed in a longitudinal study at 6-monthly intervals. Fifteen target genes and fourteen proteins involved in muscle physiology and differentiation, metabolic processes and neuromuscular junction dismantlement were studied in the three cohorts. In the muscle biopsy cohort, the risk for a higher mortality in an ALS patient that showed high Collagen type XIX, alpha 1 (COL19A1) protein levels and a fast progression of the disease was 70.5% (P < 0.05), while in the blood cohort, this risk was 20% (P < 0.01). In the serial blood cohort, the linear mixed model analysis showed a significant association between increasing COL19A1 gene levels along disease progression and a faster progression during the follow-up period of 24 months (P < 0.05). Additionally, higher COL19A1 levels and a faster progression increased 17.9% the mortality risk (P < 0.01). We provide new evidence that COL19A1 can be considered a prognostic biomarker that could help the selection of homogeneous groups of patients for upcoming clinical trial and may be pointed out as a promising therapeutic target in ALS. info:eu-repo/grantAgreement/ES/FIS/PI14-00088 info:eu-repo/grantAgreement/ES/FIS/PI17-00491 info:eu-repo/grantAgreement/ES/FIS/PI17-00949 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 5.402 2019 GERIATRICS & GERONTOLOGY 4 / 51 = 0.078 2019 Q1 T1 1.533 2019 Geriatrics and Gerontology 2019 Q1 Pathology and Forensic Medicine 2019 Q1 Neurology (clinical) 2019 Q1 Cell Biology 2019 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Atencia Cibreiro, Gabriela Torre Merino, Paz Roy, Juan F. Galiana, Adrián Juárez Rufian, Alexandra Cano, Juan M. Martin, Miguel Ángel Moreno, Laura Universidad de Zaragoza (orcid)0000-0002-7277-4318 Larrodé, Pilar Universidad de Zaragoza (orcid)0000-0001-6199-2953 Cordero Vázquez, Pilar Galan, Lucía Mora, Jesús Muñoz-Blanco, José Luis Muñoz, María J. Universidad de Zaragoza (orcid)0000-0001-8301-6902 Zaragoza, Pilar Universidad de Zaragoza (orcid)0000-0001-5740-0185 Pegoraro, Elena Sorarú, Gianni Mora, Marina Lunetta, Christian Penco, Silvana Tarlarini, Claudia Esteban, Jesús Osta, Rosario Universidad de Zaragoza (orcid)0000-0001-5687-6704 García Redondo, Alberto 1001 420 Universidad de Zaragoza Dpto. Anatom.,Embri.Genét.Ani. Área Genética 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1005 315 Universidad de Zaragoza Dpto. Farmacología y Fisiolog. Área Farmacología 10, 2 (2019), 278-292 Aging dis. Aging and disease 2152-5250 914348 http://zaguan.unizar.es/record/78988/files/texto_completo.pdf Versión publicada 139070 http://zaguan.unizar.es/record/78988/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:78988 articulos driver 2024-01-04-11:02:13 ARTICLE